经肝动脉使用 TheraSphere®行放射性栓塞治疗肝细胞癌。
Radioembolization for hepatocellular carcinoma using TheraSphere®.
机构信息
Liver Diseases Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
出版信息
Saudi J Gastroenterol. 2011 May-Jun;17(3):215-7. doi: 10.4103/1319-3767.80388.
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y90) microspheres is a new concept in radiation therapy for HCC. This review focuses on the indications, efficacy, side effects, and future direction of Y90 therapy, using TheraSphere® , in HCC patients.
RESULTS
Comprehensive literature reviews have described the clinical and scientific evidence of Y90 therapy. The Radioembolization Brachytherapy Oncology Consortium has concluded that there is sufficient evidence to support the safe and effective use of this locoregional therapy in HCC patients, including those with portal vein thrombosis.
CONCLUSIONS
There are currently no randomized clinical trials done on TheraSphere® and none of the studies so far have shown a survival benefit. Thus, although it represents a very promising therapy with excellent initial results, it cannot be fully recommended yet, till well-designed, large, randomized clinical studies are conducted showing survival benefits.
背景/目的：肝细胞癌（HCC）是肝脏最常见的原发性恶性肿瘤。钇-90（Y90）微球放射性栓塞是 HCC 放射治疗的新概念。本综述重点介绍了使用 TheraSphere®治疗 HCC 患者的 Y90 治疗的适应证、疗效、副作用和未来方向。
结果
全面的文献综述描述了 Y90 治疗的临床和科学证据。放射性栓塞近距离放射治疗肿瘤学联盟得出结论，有足够的证据支持安全有效地将这种局部区域治疗用于 HCC 患者，包括有门静脉血栓形成的患者。
结论
目前尚未对 TheraSphere®进行随机临床试验，迄今为止也没有任何研究显示生存获益。因此，尽管它具有非常有前途的初始结果，但在进行设计良好、大型、随机临床试验显示生存获益之前，尚不能完全推荐。
Zotero 插件